277 related articles for article (PubMed ID: 21803108)
21. The future of pneumococcal disease prevention.
Rodgers GL; Klugman KP
Vaccine; 2011 Sep; 29 Suppl 3():C43-8. PubMed ID: 21896352
[TBL] [Abstract][Full Text] [Related]
22. [Prevalence of serotypes causing invasive pneumococcal disease in the region of Tarragona, Spain, 2006-2009: vaccine-serotype coverage for the distinct antipneumococcal vaccine formulations].
Ochoa-Gondar O; Gómez-Bertomeu F; Vila-Córcoles A; Raga X; Aguirre C; Utrera J; de Diego C; Guzmán JA; Figuerola E;
Rev Esp Quimioter; 2015 Feb; 28(1):29-35. PubMed ID: 25690142
[TBL] [Abstract][Full Text] [Related]
23. Effectiveness of the new serotypes in the 13-valent pneumococcal conjugate vaccine.
Miller E; Andrews NJ; Waight PA; Slack MP; George RC
Vaccine; 2011 Nov; 29(49):9127-31. PubMed ID: 21983361
[TBL] [Abstract][Full Text] [Related]
24. Changing serotypes causing childhood invasive pneumococcal disease: Massachusetts, 2001-2007.
Hsu KK; Shea KM; Stevenson AE; Pelton SI;
Pediatr Infect Dis J; 2010 Apr; 29(4):289-93. PubMed ID: 19935447
[TBL] [Abstract][Full Text] [Related]
25. Geographic variation in invasive pneumococcal disease following pneumococcal conjugate vaccine introduction in the United States.
Rosen JB; Thomas AR; Lexau CA; Reingold A; Hadler JL; Harrison LH; Bennett NM; Schaffner W; Farley MM; Beall BW; Moore MR;
Clin Infect Dis; 2011 Jul; 53(2):137-43. PubMed ID: 21690620
[TBL] [Abstract][Full Text] [Related]
26. Clinical presentation of invasive pneumococcal disease in Spain in the era of heptavalent conjugate vaccine.
de Sevilla MF; García-García JJ; Esteva C; Moraga F; Hernández S; Selva L; Coll F; Ciruela P; Planes AM; Codina G; Salleras L; Jordan I; Domínguez A; Muñoz-Almagro C
Pediatr Infect Dis J; 2012 Feb; 31(2):124-8. PubMed ID: 22173137
[TBL] [Abstract][Full Text] [Related]
27. Epidemiology and evolution of invasive pneumococcal disease caused by multidrug resistant serotypes of 19A in the 8 years after implementation of pneumococcal conjugate vaccine immunization in Dallas, Texas.
Techasaensiri C; Messina AF; Katz K; Ahmad N; Huang R; McCracken GH
Pediatr Infect Dis J; 2010 Apr; 29(4):294-300. PubMed ID: 19949357
[TBL] [Abstract][Full Text] [Related]
28. Invasive pneumococcal disease in young children before licensure of 13-valent pneumococcal conjugate vaccine - United States, 2007.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2010 Mar; 59(9):253-7. PubMed ID: 20224541
[TBL] [Abstract][Full Text] [Related]
29. Incidence of invasive pneumococcal disease among individuals with sickle cell disease before and after the introduction of the pneumococcal conjugate vaccine.
Halasa NB; Shankar SM; Talbot TR; Arbogast PG; Mitchel EF; Wang WC; Schaffner W; Craig AS; Griffin MR
Clin Infect Dis; 2007 Jun; 44(11):1428-33. PubMed ID: 17479937
[TBL] [Abstract][Full Text] [Related]
30. Impact and effectiveness of 23-valent pneumococcal polysaccharide vaccine against invasive pneumococcal disease in the elderly in England and Wales.
Andrews NJ; Waight PA; George RC; Slack MP; Miller E
Vaccine; 2012 Nov; 30(48):6802-8. PubMed ID: 23000122
[TBL] [Abstract][Full Text] [Related]
31. Implication of pneumococcal conjugate vaccines to public health: Thailand perspective.
Wongsawat J; Chokephaibulkit K
J Med Assoc Thai; 2010 Nov; 93 Suppl 5():S53-60. PubMed ID: 21294383
[TBL] [Abstract][Full Text] [Related]
32. Impact of the pneumococcal conjugate vaccine on pneumococcal parapneumonic empyema.
Byington CL; Korgenski K; Daly J; Ampofo K; Pavia A; Mason EO
Pediatr Infect Dis J; 2006 Mar; 25(3):250-4. PubMed ID: 16511389
[TBL] [Abstract][Full Text] [Related]
33. Invasive pneumococcal disease in children 5 years after conjugate vaccine introduction--eight states, 1998-2005.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2008 Feb; 57(6):144-8. PubMed ID: 18272956
[TBL] [Abstract][Full Text] [Related]
34. Streptococcus pneumoniae serotypes in Utah adults at the end of the PCV7 era.
Kendall BA; Dascomb KK; Mehta RR; Mason EO; Ampofo K; Pombo DJ; Pavia AT; Byington CL
Vaccine; 2011 Nov; 29(49):9123-6. PubMed ID: 22001280
[TBL] [Abstract][Full Text] [Related]
35. Population-based surveillance for invasive pneumococcal disease and pneumonia in infants and young children in Bogotá, Colombia.
Benavides JA; Ovalle OO; Salvador GR; Gray S; Isaacman D; Rodgers GL
Vaccine; 2012 Aug; 30(40):5886-92. PubMed ID: 22484295
[TBL] [Abstract][Full Text] [Related]
36. Regional differences in serotype distribution, pneumococcal vaccine coverage, and antimicrobial resistance of invasive pneumococcal disease among German federal states.
Imöhl M; Reinert RR; van der Linden M
Int J Med Microbiol; 2010 Apr; 300(4):237-47. PubMed ID: 19604721
[TBL] [Abstract][Full Text] [Related]
37. Current knowledge regarding the investigational 13-valent pneumococcal conjugate vaccine.
Dinleyici EC; Yargic ZA
Expert Rev Vaccines; 2009 Aug; 8(8):977-86. PubMed ID: 19627181
[TBL] [Abstract][Full Text] [Related]
38. Changing epidemiology of invasive pneumococcal disease in Canada, 1998-2007: update from the Calgary-area Streptococcus pneumoniae research (CASPER) study.
Kellner JD; Vanderkooi OG; MacDonald J; Church DL; Tyrrell GJ; Scheifele DW
Clin Infect Dis; 2009 Jul; 49(2):205-12. PubMed ID: 19508165
[TBL] [Abstract][Full Text] [Related]
39. Herd immunity and pneumococcal conjugate vaccine: a quantitative model.
Haber M; Barskey A; Baughman W; Barker L; Whitney CG; Shaw KM; Orenstein W; Stephens DS
Vaccine; 2007 Jul; 25(29):5390-8. PubMed ID: 17583392
[TBL] [Abstract][Full Text] [Related]
40. Reduction in high rates of antibiotic-nonsusceptible invasive pneumococcal disease in tennessee after introduction of the pneumococcal conjugate vaccine.
Talbot TR; Poehling KA; Hartert TV; Arbogast PG; Halasa NB; Mitchel E; Schaffner W; Craig AS; Edwards KM; Griffin MR
Clin Infect Dis; 2004 Sep; 39(5):641-8. PubMed ID: 15356776
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
